WO2016200101A3 - 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 - Google Patents

트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
WO2016200101A3
WO2016200101A3 PCT/KR2016/005911 KR2016005911W WO2016200101A3 WO 2016200101 A3 WO2016200101 A3 WO 2016200101A3 KR 2016005911 W KR2016005911 W KR 2016005911W WO 2016200101 A3 WO2016200101 A3 WO 2016200101A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivative compound
same
tricyclic derivative
tankyrase
pharmaceutical composition
Prior art date
Application number
PCT/KR2016/005911
Other languages
English (en)
French (fr)
Other versions
WO2016200101A2 (ko
Inventor
이현호
천광우
조보영
김은선
장은성
오형찬
김정민
박지선
이한창
Original Assignee
제일약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2990277A priority Critical patent/CA2990277C/en
Priority to ES16807741T priority patent/ES2870203T3/es
Priority to CN201680040992.8A priority patent/CN107849040B/zh
Priority to PL16807741T priority patent/PL3312177T3/pl
Priority to AU2016276806A priority patent/AU2016276806B9/en
Priority to MX2017016013A priority patent/MX2017016013A/es
Priority to EP16807741.0A priority patent/EP3312177B1/en
Application filed by 제일약품주식회사 filed Critical 제일약품주식회사
Priority to US15/579,692 priority patent/US10464919B2/en
Priority to NZ738187A priority patent/NZ738187A/en
Priority to RU2017146130A priority patent/RU2715413C2/ru
Priority to DK16807741.0T priority patent/DK3312177T3/da
Priority to BR112017026392-0A priority patent/BR112017026392B1/pt
Priority to MYPI2017704653A priority patent/MY194590A/en
Priority to JP2017564557A priority patent/JP2018521033A/ja
Publication of WO2016200101A2 publication Critical patent/WO2016200101A2/ko
Publication of WO2016200101A3 publication Critical patent/WO2016200101A3/ko
Priority to PH12017502228A priority patent/PH12017502228A1/en
Priority to SA517390509A priority patent/SA517390509B1/ar
Priority to ZA2017/08663A priority patent/ZA201708663B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

본 발명은 신규한 트리사이클릭 유도체 화합물에 관한 것으로서, 보다 상세하게는 우수한 PARP-1. 탄키라제-1 또는 탄키라제-2 저해 활성을 갖는 트리사이클릭 유도체 화합물, 이의 광학이성질체, 이의 라세미체 또는 이의 약학적으로 허용가능한 염에 관한 것이다. 본 발명에 따른 트리사이클릭 유도체 화합물, 이의 광학이성질체, 이의 라세미체 또는 이의 약학적으로 허용 가능한 염은 PARP-1. 탄키라제-1 또는 탄키라제-2 저해 활성을 통하여 신경병리성 동통, 신경퇴화질환, 심혈관계 질환, 당뇨로 인한 신경병증, 염증성 질환, 골다공증 또는 암의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2016/005911 2015-06-09 2016-06-03 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물 WO2016200101A2 (ko)

Priority Applications (17)

Application Number Priority Date Filing Date Title
MYPI2017704653A MY194590A (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
CN201680040992.8A CN107849040B (zh) 2015-06-09 2016-06-03 三环衍生化合物、其制备方法、和含有其的药物组合物
PL16807741T PL3312177T3 (pl) 2015-06-09 2016-06-03 Związek tricyklicznej pochodnej, jego sposób wytwarzania i zawierająca go kompozycja farmaceutyczna
AU2016276806A AU2016276806B9 (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
MX2017016013A MX2017016013A (es) 2015-06-09 2016-06-03 Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.
EP16807741.0A EP3312177B1 (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
RU2017146130A RU2715413C2 (ru) 2015-06-09 2016-06-03 Трициклическое производное соединение, способ его получения и фармацевтическая композиция, содержащая такое соединение
US15/579,692 US10464919B2 (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
NZ738187A NZ738187A (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
CA2990277A CA2990277C (en) 2015-06-09 2016-06-03 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
DK16807741.0T DK3312177T3 (da) 2015-06-09 2016-06-03 Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme
BR112017026392-0A BR112017026392B1 (pt) 2015-06-09 2016-06-03 Composto derivado tricíclico, método para sua preparação e seu uso
ES16807741T ES2870203T3 (es) 2015-06-09 2016-06-03 Compuesto derivado tricíclico, método para prepararlo y composición farmacéutica que comprende el mismo
JP2017564557A JP2018521033A (ja) 2015-06-09 2016-06-03 三環式誘導体化合物、その製造方法及びそれを含む薬学的組成物
PH12017502228A PH12017502228A1 (en) 2015-06-09 2017-12-07 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
SA517390509A SA517390509B1 (ar) 2015-06-09 2017-12-07 مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه
ZA2017/08663A ZA201708663B (en) 2015-06-09 2017-12-19 Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150081021 2015-06-09
KR10-2015-0081021 2015-06-09

Publications (2)

Publication Number Publication Date
WO2016200101A2 WO2016200101A2 (ko) 2016-12-15
WO2016200101A3 true WO2016200101A3 (ko) 2017-02-02

Family

ID=57503424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/005911 WO2016200101A2 (ko) 2015-06-09 2016-06-03 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물

Country Status (21)

Country Link
US (1) US10464919B2 (ko)
EP (1) EP3312177B1 (ko)
JP (2) JP2018521033A (ko)
KR (1) KR101837047B1 (ko)
CN (1) CN107849040B (ko)
AU (1) AU2016276806B9 (ko)
BR (1) BR112017026392B1 (ko)
CA (1) CA2990277C (ko)
CL (1) CL2017003138A1 (ko)
DK (1) DK3312177T3 (ko)
ES (1) ES2870203T3 (ko)
MX (1) MX2017016013A (ko)
MY (1) MY194590A (ko)
NZ (1) NZ738187A (ko)
PH (1) PH12017502228A1 (ko)
PL (1) PL3312177T3 (ko)
PT (1) PT3312177T (ko)
RU (1) RU2715413C2 (ko)
SA (1) SA517390509B1 (ko)
WO (1) WO2016200101A2 (ko)
ZA (1) ZA201708663B (ko)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949562B (zh) 2015-06-09 2021-07-23 拜耳制药股份公司 毒蕈碱性m2受体的正性变构调节剂
NZ738187A (en) * 2015-06-09 2019-03-29 Je Il Pharmaceutical Co Ltd Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
JP2022527590A (ja) * 2019-04-09 2022-06-02 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物
AU2020318599B2 (en) * 2019-07-19 2023-09-07 Astrazeneca Ab PARP1 inhibitors
JP2022551373A (ja) * 2019-07-29 2022-12-09 ジェイル ファーマシューティカル カンパニー リミテッド 三環式誘導体を用いた脳卒中の治療方法
JP2022544776A (ja) * 2019-08-14 2022-10-21 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022225934A1 (en) * 2021-04-19 2022-10-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
BR112023021383A2 (pt) * 2021-04-22 2023-12-19 Wigen Biomedicine Tech Shanghai Co Ltd Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
CA3219248A1 (en) 2021-05-18 2022-11-24 Hyun Ju Cha Parp inhibitor-resistant cancer therapeutic agent
CA3219303A1 (en) 2021-05-18 2022-11-24 Onconic Therapeutics Inc. Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2023011608A1 (zh) * 2021-08-05 2023-02-09 上海枢境生物科技有限公司 含三并环类衍生物调节剂、其制备方法和应用
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
TW202332438A (zh) * 2021-12-22 2023-08-16 美商思諾維新醫藥公司 Ｐａｒｐ１抑制劑
CN116425744A (zh) * 2022-01-13 2023-07-14 优领医药科技(香港)有限公司 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
WO2023169226A1 (en) * 2022-03-11 2023-09-14 Impact Therapeutics (Shanghai), Inc Substituted tricyclic compounds as parp inhibitors and the use thereof
TW202400596A (zh) 2022-04-28 2024-01-01 美商辛瑟拉股份有限公司 三環parp1抑制劑及其用途
WO2023217045A1 (zh) * 2022-05-07 2023-11-16 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
WO2005123687A1 (de) * 2004-06-16 2005-12-29 Sanofi-Aventis Deutschland Gmbh Substituierte tetrahydro-2h-isochinolin-1-on-derivate, verfahren zu ihrer herstellung und ihre verwendung als medikament
KR20090046431A (ko) * 2007-11-06 2009-05-11 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
WO2010056038A2 (ko) * 2008-11-11 2010-05-20 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR20130089089A (ko) * 2012-02-01 2013-08-09 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
DK2061765T3 (en) * 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
NZ738187A (en) * 2015-06-09 2019-03-29 Je Il Pharmaceutical Co Ltd Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
WO2005123687A1 (de) * 2004-06-16 2005-12-29 Sanofi-Aventis Deutschland Gmbh Substituierte tetrahydro-2h-isochinolin-1-on-derivate, verfahren zu ihrer herstellung und ihre verwendung als medikament
KR20090046431A (ko) * 2007-11-06 2009-05-11 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
WO2010056038A2 (ko) * 2008-11-11 2010-05-20 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR20130089089A (ko) * 2012-02-01 2013-08-09 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법

Also Published As

Publication number Publication date
KR20160144916A (ko) 2016-12-19
EP3312177B1 (en) 2021-04-14
PH12017502228A1 (en) 2018-06-11
CN107849040A (zh) 2018-03-27
ES2870203T3 (es) 2021-10-26
PL3312177T3 (pl) 2021-11-02
MX2017016013A (es) 2018-04-20
BR112017026392B1 (pt) 2023-12-26
BR112017026392A2 (ko) 2018-08-21
JP6806969B2 (ja) 2021-01-06
RU2017146130A (ru) 2019-07-16
AU2016276806A1 (en) 2018-01-04
AU2016276806B2 (en) 2019-02-14
CA2990277C (en) 2021-10-26
PT3312177T (pt) 2021-05-17
EP3312177A4 (en) 2018-12-05
RU2715413C2 (ru) 2020-02-28
DK3312177T3 (da) 2021-07-05
NZ738187A (en) 2019-03-29
US10464919B2 (en) 2019-11-05
JP2019163287A (ja) 2019-09-26
JP2018521033A (ja) 2018-08-02
ZA201708663B (en) 2019-04-24
CN107849040B (zh) 2021-04-06
CA2990277A1 (en) 2016-12-15
US20180162834A1 (en) 2018-06-14
CL2017003138A1 (es) 2018-06-15
AU2016276806B9 (en) 2019-02-21
KR101837047B1 (ko) 2018-03-09
EP3312177A2 (en) 2018-04-25
RU2017146130A3 (ko) 2019-07-17
SA517390509B1 (ar) 2021-06-02
MY194590A (en) 2022-12-05
WO2016200101A2 (ko) 2016-12-15

Similar Documents

Publication Publication Date Title
WO2016200101A3 (ko) 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
WO2016172134A3 (en) Novel compounds
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12018502507A1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
WO2017035413A3 (en) Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2017001936A3 (en) Therapeutic inhibitory compounds
WO2017001926A8 (en) Therapeutic inhibitory compounds
WO2015066426A3 (en) Angiopoietin-based interventions for treating cerebral malaria
WO2019226213A3 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
WO2017042828A3 (en) Process for the preparation of selexipag
EP3417853A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER CONTAINING POLYPHENOL COMPOUND AS ACTIVE INGREDIENT
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
WO2017009257A3 (en) Pectin compositions for preventing and treating inflammatory diseases
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EP3395804A4 (en) NOVEL SPIROCHINONE DERIVATIVE COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREFORE AS AN ACTIVE AGENT FOR PREVENTING OR TREATING NEUROLOGICAL ILLNESSES
WO2018060962A3 (en) Metformin amino acid compounds and methods of using the same
WO2015001541A3 (en) Pharmaceutical film composition
WO2017034242A3 (ko) 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
WO2017064635A3 (en) Saroglitazar magnesium, compositions containing it, process for its preparation
WO2017106367A8 (en) Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16807741

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15579692

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12017502228

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2990277

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/016013

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2017564557

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016276806

Country of ref document: AU

Date of ref document: 20160603

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017146130

Country of ref document: RU

Ref document number: 2016807741

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017026392

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017026392

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171207